FDA panel thumbs down on Correvio’s Brinavess for afib

The FDA’s Cardiovascular and Renal Drugs Advisory Committee has voted 11-2 against approval of Correvio Pharma’s (NASDAQ:CORV) Brinavess (vernakalant hydrochloride, IV) for the rapid conversion of recent onset atrial fibrillation (AF) in adults.

Shares are currently halted, but longs should expect a significant down move upon resumption of trade.

https://seekingalpha.com/news/3525318-fda-advisory-committee-thumbs-down-on-correvios-brinavess-for-af